Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Xofigo Patient Case Studies

Bayer has collaborated with healthcare professionals across the multidisciplinary team to develop a series of patient case studies. These case studies were developed as a promotional educational resource and share real-world experience from experts on the treatment and management of their patients with metastatic castration-resistant prostate cancer (mCRPC). Each case study covers the whole patient journey, from initial diagnosis and treatment decisions to outcomes and tolerability.


These case studies share a range of different patient profiles including different ages, treatment histories, concomitant medications and outcomes to help visualise and identify eligible mCRPC patients who may be suitable for treatment with Xofigo.


Xofigo Patient Case Study: An Oncologist perspective

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

By Dr Aspasia Soultati, Consultant Medical Oncologist, Brighton and Sussex University Hospital, NHS Foundation Trust, Brighton


Patient: 89 years old when diagnosed with advanced prostate cancer who was chemo-ineligible due to his age, comorbidities, and performance status.


Treatment goal: Improve symptomatic control of bone pain and slow down the decline of quality of life during on-treatment period vs placebo.1 4th line treatment with Xofigo

This patient case study is initiated and funded by Bayer plc. No patient identifiable data or photos of patients are shared within these case studies and the appropriate consent from the patients was collected by the HCP prior to development. Individual responses and experiences to medicinal products may vary.


Dr Aspasia Soultati

Dr Aspasia Soultati

Dr Aspasia Soultati is a Medical Oncologist with a specialist interest in Genitourinary and Colorectal cancers. She completed her specialty training in Athens, Greece and Guys & St Thomas, London. Aspasia has a strong research interest having obtained a PhD in Athens, and her post-doctoral translational research was in Renal cancers with a team of world renowned scientists, led by Professor C Swanton, at the Francis Crick Institute, London.


Currently, she treats patients with Colorectal and GI cancers at Eastbourne District General Hospital (EDGH) and is the Oncology Lead for the unit at Eastbourne and Conquest. Aspasia is currently responsible for the delivery of chemotherapy and the holistic care of colorectal and urology oncology patients across Eastbourne and Hastings. She supervises a team of mixed workforce professionals including pharmacists, CNS and physician associates who are currently reviewing patients in clinic under our guidance and support.


As part of her Leadership role she has designed, proposed, and co led the strategic development, reconfiguration, and expansion on the EDGH oncology service, with the deployment of new methods of service provision (consultant Led service mixed workforce model). Her aspiration is to help transform the experience of oncology patients receiving treatment across Sussex through promoting high quality clinical practice and encouraging clinical research.

Click below to view other Xofigo Patient Case Studies:

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.


Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email:


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.